

Annexure-III

Sr. No.	Details of the party (listed entity /subsidiary) entering into the transaction	Details of the counterparty		Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction	
		Name	Relationship of the counterparty with the listed entity or its subsidiary						Opening balance	Closing balance
1	Novartis India Limited	Novartis AG	Holding Company	Any other transaction	Royalty expenses	44.33	None	12.87	12.92	12.20
2		Novartis-Mitarbeiterbeteiligungsstiftung (MBS)	Fellow Subsidiary	Any other transaction	Purchase of shares	10.00	None	0.13	2.83	1.74
3		Novartis India Limited Employees' Provident Fund	Fellow Subsidiary	Any other transaction	Contribution to In-house Trust for Post Employment Benefits	120.00	None	3.30	0.00	0.00
4		Novartis Pharma AG	Fellow Subsidiary	Purchase of goods or services		3000.00	None	502.27	155.80	150.10
5		Novartis Healthcare Private Limited	Fellow Subsidiary	Sale of goods or services		11.00	None	4.37	0.81	0.84
6		Novartis Healthcare Private Limited	Fellow Subsidiary	Any other transaction	Business Support Services	37.28	None	15.01	0.89	3.05
7		Novartis Healthcare Private Limited	Fellow Subsidiary	Purchase of goods or services		30.00	None	12.20	7.15	2.31
8		Novartis Healthcare Private Limited	Fellow Subsidiary	Any other transaction	Commission Income	1.00	None	0.06	0.03	0.17
9		Novartis Healthcare Private Limited	Fellow Subsidiary	Purchase of goods or services		60.00	None	26.95	4.49	5.08
10		Ms. Sandra Martyres	Independent Director	Any other transaction	Sitting fees	0.20	None	0.20	0.00	0.00
11		Mr. Sanker Parameswaran	Independent Director	Any other transaction	Sitting fees	0.20	None	0.20	0.00	0.00
12		Ms. Gira Sardesai	Independent Director	Any other transaction	Sitting fees	0.20	None	0.20	0.00	0.00
Total value of transaction during the reporting period								577.76		